Figure 5.
Subgroup analyses of PFS comparing ibrutinib plus rituximab vs ibrutinib monotherapy (above), and the impact of CXCR4 mutations on VGPR within each treatment arm (below). False discovery rate correction was applied for multiple comparisons: 7 subgroup comparisons (above) and 2 (below).

Subgroup analyses of PFS comparing ibrutinib plus rituximab vs ibrutinib monotherapy (above), and the impact of CXCR4 mutations on VGPR within each treatment arm (below). False discovery rate correction was applied for multiple comparisons: 7 subgroup comparisons (above) and 2 (below).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal